4x from a deal with Ukraine?

(Full access for Lifetime Members only)

4x from a deal with Ukraine?

16 July 2024

The stock featured in this report is a potentially truly remarkable case. It could turn out to be so mispriced as to be almost unbelievably cheap. However, the figures all add up.

This investment depends on Russian equities becoming tradeable again in some shape or form. An unlikely scenario? The stock has started to move, but the upside is still surprisingly high.

It could take a long time, but if there's a sniff of relations improving, the stock could move quite quickly – as, indeed, it has started to do over the past few days. The improving odds for a re-election of Donald J. Trump as US president are just one of the factors at work. Other investors may have started to buy into the stock because they view it as a way to diversify their portfolio towards a different geopolitical block.

In any case, it's a peculiar case and one that could turn out to be rather profitable.

Liquidity is an issue for anyone interested in this stock, though.

This opportunity is therefore exclusively available to Undervalued-Shares.com Lifetime Members.

Not a Lifetime Member yet? Sign up for a Membership - just USD 999/one-off.
Already a Lifetime Member? Log into your account to download the report.

Most recent

Sark – it’s not a big deal

Sark – it’s not a big deal

I had mobilised GBP 30m to buy a portfolio of real estate in Sark, with plans to IPO the company. How did it go, and what may happen next?

read more

Latest reports (for Members only)

2-2.5x from an investment holding liquidation

2-2.5x from an investment holding liquidation

This AIM-listed small-cap will likely return all its capital to shareholders. Underresearched by investors, it's an opportunity that shouldn't even exist – but it does.

Ukraine reconstruction: one stock to benefit

Ukraine reconstruction: one stock to benefit

If or when the war in Ukraine ends, this stock will likely become the focus of investor money pushing into the country.

Actinium-225, aka "the world's rarest drug"

Actinium-225, aka "the world's rarest drug"

This little-known Western European company could become the global market leader for supplying the uber-rare "Ac-225", a potent weapon to treat cancer.